![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-desktop-headergif-12950.gif)
![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-mobgif-20656.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/olverembatinib-approved-for-commercialization-in-macau-china-302190451.html
https://www.prnewswire.com/news-releases/ascentage-pharma-received-us100-million-option-payment-from-takeda-302189330.html
https://www.prnewswire.com/news-releases/ascentage-pharma-announces-confidential-submission-of-draft-registration-statement-for-proposed-initial-public-offering-of-american-depositary-shares-302179764.html
https://www.prnewswire.com/news-releases/ascentage-pharma-announces-closing-of-us75-million-equity-investment-by-takeda-302178650.html
https://www.prnewswire.com/news-releases/live-from-eha-2024--ascentage-pharma-releases-updated-data-of-lisaftoclax-in-patients-with-rr-mm-and-al-amyloidosis-highlighting-marked-improvement-in-orr-302175033.html
https://www.prnewswire.com/news-releases/live-from-eha-2024--posters-featuring-results-from-three-studies-of-olverembatinib-including-encouraging-data-from-us-study-in-cml-and-ph-all-302175024.html
https://www.fiercepharma.com/pharma/takeda-signs-potentially-rival-novartis-option-deal-ascentage-pharmas-leukemia-tki
https://www.prnewswire.com/news-releases/ascentage-pharma-signs-option-agreement-with-takeda-to-enter-into-exclusive-global-license-for-olverembatinib-a-third-generation-bcr-abl-tyrosine-kinase-inhibitor-tki-302173047.html